Literature DB >> 25305056

Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.

Vincenzo Marotta1, Carolina Di Somma, Manila Rubino, Concetta Sciammarella, Roberta Modica, Luigi Camera, Michela Del Prete, Francesca Marciello, Valeria Ramundo, Luisa Circelli, Pasqualina Buonomano, Annamaria Colao, Antongiulio Faggiano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25305056     DOI： 10.1007/s12020-014-0448-y

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  20 in total

1.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

2.  Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

Authors:  Maria E Cabanillas; Steven G Waguespack; Yulia Bronstein; Michelle D Williams; Lei Feng; Mike Hernandez; Adriana Lopez; Steven I Sherman; Naifa L Busaidy
Journal:  J Clin Endocrinol Metab       Date:  2010-04-14       Impact factor: 5.958

Review 3.  Sequential use of targeted agents in the treatment of renal cell carcinoma.

Authors:  Thomas E Hutson; Ronald M Bukowski; C Lance Cowey; Robert Figlin; Bernard Escudier; Cora N Sternberg
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-11       Impact factor: 6.312

4.  Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

Authors:  Laurie L Carr; David A Mankoff; Bernardo H Goulart; Keith D Eaton; Peter T Capell; Elizabeth M Kell; Julie E Bauman; Renato G Martins
Journal:  Clin Cancer Res       Date:  2010-09-16       Impact factor: 12.531

5.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

Review 6.  Targeted therapy with kinase inhibitors in aggressive endocrine tumors.

Authors:  Vincenzo Marotta; Maria Domenica Franzese; Michela Del Prete; Maria Grazia Chiofalo; Valeria Ramundo; Raffaella Esposito; Francesca Marciello; Luciano Pezzullo; Annachiara Carratù; Mario Vitale; Annamaria Colao; Antongiulio Faggiano
Journal:  Expert Opin Pharmacother       Date:  2013-06       Impact factor: 3.889

7.  Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.

Authors:  Vincenzo Marotta; Valeria Ramundo; Luigi Camera; Michela Del Prete; Rosa Fonti; Raffaella Esposito; Giovannella Palmieri; Marco Salvatore; Mario Vitale; Annamaria Colao; Antongiulio Faggiano
Journal:  Clin Endocrinol (Oxf)       Date:  2013-05       Impact factor: 3.478

8.  Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.

Authors:  Juan J Díez; Pedro Iglesias; Teresa Alonso; Enrique Grande
Journal:  Endocrine       Date:  2014-07-17       Impact factor: 3.633

Review 9.  Progress in molecular-based management of differentiated thyroid cancer.

Authors:  Mingzhao Xing; Bryan R Haugen; Martin Schlumberger
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

10.  Phase II trial of sorafenib in metastatic thyroid cancer.

Authors:  Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more
  2 in total

1.  Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.

Authors:  Marco Gallo; Federica Michelon; Anna Castiglione; Francesco Felicetti; Alessandro Adriano Viansone; Alice Nervo; Clizia Zichi; Giovannino Ciccone; Alessandro Piovesan; Emanuela Arvat
Journal:  Endocrine       Date:  2014-11-21       Impact factor: 3.633

2.  Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis.

Authors:  Shi-Tong Yu; Jun-Na Ge; Jing-Yi Luo; Zhi-Gang Wei; Bai-Hui Sun; Shang-Tong Lei
Journal:  Cancer Manag Res       Date:  2019-02-14       Impact factor: 3.989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.